Trial Information

Summary: PRIOR Study - A Study of Boniva (Ibandronate) in Postmenopausal Women With Osteoporosis or Osteopenia

Status: Completed

Protocol Number: ML18058

Sponsor: Roche Laboratories Inc.

Company Division: Pharmaceutical

Official Scientific Title: An open-label study of level of treatment adherence to monthly oral or every 3-month intravenous Bonviva in women with post-menopausal osteoporosis who are intolerant to daily or weekly alendronate or risendronate therapy

Brief Summary: The purpose of this study is to evaluate treatment adherence to different regimens of Bonviva in postmenopausal women with osteoporosis or osteopenia who are intolerant to daily or weekly alendronate or risedronate therapy due to gastrointestinal (GI) side effects. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals. Target sample size is 515.

Study Phase: IV

Study Design / Study Details:

  • Purpose: Treatment
  • Allocation: Non-Randomized
  • Masking: Open Label
  • Control: Uncontrolled
  • Assignment: Parallel
  • Endpoints: Safety

Study Type:

Interventional

Condition: Post-Menopausal Osteoporosis

Intervention Type: Drug

Intervention Name: ibandronate[Bonviva/Boniva]

Primary Outcome: 1. Proportion of patients who have >=75% adherence using either monthly oral Bonviva or quarterly IV Bonviva

Key Secondary Outcomes: 1. Severity and frequency of GI events, and proportion of patients who have a change in pattern of GI events, at screening and months 3 and 10; Safety: adverse events, laboratory tests

Inclusion Criteria:

  • women with postmenopausal osteoporosis or osteopenia;
  • discontinuation of daily and /or weekly alendronate or risedronate therapy because of GI intolerance (eg, heartburn, acid reflux, stomach upset).

Exclusion Criteria:

  • inability to stand or sit upright for 60 minutes;
  • inability to swallow a tablet whole;
  • hypersensitivity to any component of Boniva;
  • malignant disease diagnosed within previous 10 years (except resected basal cell cancer);
  • contraindications for calcium or vitamin D therapy;
  • patients who do not fulfill a minimum 3 months wash-out therapy from any previous bisphosphonate therapy.

Gender: Females

Age Limits: Min: Years

Accepts Healthy Volunteers: No

Trial Registration Date: 08/30/2005

Date Last Updated: 09/19/2008

Link To Trial Results

Contact:

Research Site:
Located In:
Lake Havasu City, AZ 86403
Telephone: 973-235-5000 or 800-526-6367

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 2:57:17 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA